Overview

Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression Whe

Status:
Withdrawn

Trial end date:
2008-05-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if either of two doses of EMD 273066 when given with a low dose of cyclophosphamide will result in a second time to progression that is as long or longer than the first time to progression

Phase:

Phase 2

Details

Lead Sponsor:

EMD Serono

Treatments:

Cyclophosphamide